Anti-CDKN2A/p19ARF antibody [12-A1]
| Name | Anti-CDKN2A/p19ARF antibody [12-A1] |
|---|---|
| Supplier | Abcam |
| Catalog | ab26911 |
| Prices | $379.00 |
| Sizes | 100 µg |
| Host | Rat |
| Clonality | Monoclonal |
| Isotype | IgG2b |
| Clone | 12-A1 |
| Applications | ICC/IF ICC/IF IP WB |
| Species Reactivities | Mouse |
| Antigen | Synthetic peptide conjugated to KLH derived from within residues 50 to the C-terminus of Mouse p19ARF |
| Description | Rat Monoclonal |
| Gene | Cdkn2a |
| Conjugate | Unconjugated |
| Supplier Page | Shop |
Product images
![Lane 1 : MarkerLanes 2 - 3 : Anti-CDKN2A/p19ARF antibody [12-A1] (ab26911) at 1 µg/mlLane 1 : As aboveLane 2 : mouse embryonic fibroblast total cell extract, with the p19ARF gene knocked out as a negative control at 20 µgLane 3 : mouse embryonic fibroblast total cell extract at 20 µgSecondaryLanes 2 - 3 : Rat IgG secondary antibody (ab28447) at 1/10000 dilutionPerformed under reducing conditions.](http://www.bioprodhub.com/system/product_images/ab_products/2/sub_1/27080_ab26911%2520cropped%2520copy.jpg)
Lane 1 : MarkerLanes 2 - 3 : Anti-CDKN2A/p19ARF antibody [12-A1] (ab26911) at 1 µg/mlLane 1 : As aboveLane 2 : mouse embryonic fibroblast total cell extract, with the p19ARF gene knocked out as a negative control at 20 µgLane 3 : mouse embryonic fibroblast total cell extract at 20 µgSecondaryLanes 2 - 3 : Rat IgG secondary antibody (ab28447) at 1/10000 dilutionPerformed under reducing conditions.
Product References
The AKT-mTOR pathway plays a critical role in the development of leiomyosarcomas. - The AKT-mTOR pathway plays a critical role in the development of leiomyosarcomas.
Hernando E, Charytonowicz E, Dudas ME, Menendez S, Matushansky I, Mills J, Socci ND, Behrendt N, Ma L, Maki RG, Pandolfi PP, Cordon-Cardo C. Nat Med. 2007 Jun;13(6):748-53. Epub 2007 May 13.
Monoclonal antibodies to the mouse p19(Arf) tumor suppressor protein. - Monoclonal antibodies to the mouse p19(Arf) tumor suppressor protein.
Bertwistle D, Zindy F, Sherr CJ, Roussel MF. Hybrid Hybridomics. 2004 Oct;23(5):293-300.